The 36-month beta value for LAB is also noteworthy at 1.60. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LAB is 360.49M, and at present, short sellers hold a 3.74% of that float. The average trading volume of LAB on March 05, 2025 was 1.89M shares.
LAB) stock’s latest price update
Standard BioTools Inc (NASDAQ: LAB)’s stock price has gone rise by 4.95 in comparison to its previous close of 1.01, however, the company has experienced a -15.87% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-02-27 that SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
LAB’s Market Performance
Standard BioTools Inc (LAB) has experienced a -15.87% fall in stock performance for the past week, with a -31.61% drop in the past month, and a -41.76% drop in the past quarter. The volatility ratio for the week is 12.21%, and the volatility levels for the past 30 days are at 8.57% for LAB. The simple moving average for the last 20 days is -18.02% for LAB’s stock, with a simple moving average of -43.95% for the last 200 days.
Analysts’ Opinion of LAB
TD Cowen, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.50. The rating they have provided for LAB stocks is “Buy” according to the report published on April 16th, 2024.
Jefferies gave a rating of “Buy” to LAB, setting the target price at $3.25 in the report published on April 04th of the previous year.
LAB Trading at -33.15% from the 50-Day Moving Average
After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.13% of loss for the given period.
Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 12.21%, as shares sank -27.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.04% lower at present.
During the last 5 trading sessions, LAB fell by -15.87%, which changed the moving average for the period of 200-days by -58.27% in comparison to the 20-day moving average, which settled at $1.2930. In addition, Standard BioTools Inc saw -39.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LAB starting from Black Jeffrey G., who proposed sale 57,971 shares at the price of $2.12 back on Nov 12 ’24. After this action, Black Jeffrey G. now owns shares of Standard BioTools Inc, valued at $123,098 using the latest closing price.
Taich Adam, the Former Officer of Standard BioTools Inc, proposed sale 45,851 shares at $2.00 during a trade that took place back on Sep 09 ’24, which means that Taich Adam is holding shares at $91,725 based on the most recent closing price.
Stock Fundamentals for LAB
Current profitability levels for the company are sitting at:
- -0.83 for the present operating margin
- 0.48 for the gross margin
The net margin for Standard BioTools Inc stands at -0.8. The total capital return value is set at -0.27. Equity return is now at value -43.75, with -29.69 for asset returns.
Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -4.35.
Currently, EBITDA for the company is -175.24 million with net debt to EBITDA at 0.99. When we switch over and look at the enterprise to sales, we see a ratio of 1.5. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.70.
Conclusion
In summary, Standard BioTools Inc (LAB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
